Literature DB >> 1649019

Human recombinant erythropoietin directly stimulates B cell immunoglobulin production and proliferation in serum-free medium.

H Kimata1, A Yoshida, C Ishioka, S Masuda, R Sasaki, H Mikawa.   

Abstract

The effect of human recombinant erythropoietin (Epo) on B cell responses was studied in a serum-free medium. Epo enhanced IgM production and thymidine uptake by a human IgM-producing lymphoblastoid cell line, CBL. This effect was specific to Epo since enhancement was blocked by anti-Epo antibody but not by control antibody. Among the various cytokines, interleukin-4 (IL-4) enhanced IgM production and thymidine uptake while IL-6 enhanced IgM production without affecting thymidine uptake. In contrast, other cytokines including IL-1 beta, IL-2, IL-5, interferon-alpha (IFN-alpha), interferon-gamma (IFN-gamma), or granulocyte/macrophage colony-stimulating factor (GM-CSF) were without effect. However, the enhancing effect of Epo is different from that of IL-4 or IL-6, since Epo effect was not blocked by anti-IL-4 antibody or anti-IL-6 antibody. Moreover, specific binding of Epo was detected on CBL cells. Epo also enhanced immunoglobulin (IgG, IgM and IgA) production and thymidine uptake by purified tonsil small resting B cells stimulated by Staphylococcus aureus Cowan strain I (SAC) or by large activated B cells. In contrast, Epo had no effect on unstimulated small resting B cells. These results indicate that Epo could directly stimulate activated and differentiated B cells and could enhance B cell immunoglobulin production and proliferation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1649019      PMCID: PMC1535707          DOI: 10.1111/j.1365-2249.1991.tb05696.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  23 in total

1.  Characterization of erythropoietin receptor of murine erythroid cells.

Authors:  R Sasaki; S Yanagawa; K Hitomi; H Chiba
Journal:  Eur J Biochem       Date:  1987-10-01

2.  Subset of natural killer cells is induced by immune complexes to display Fc receptors for IgE and IgA and demonstrates isotype regulatory function.

Authors:  H Kimata; A Saxon
Journal:  J Clin Invest       Date:  1988-07       Impact factor: 14.808

3.  Interleukin-3 is a differentiation factor for human basophils.

Authors:  P Valent; G Schmidt; J Besemer; P Mayer; G Zenke; E Liehl; W Hinterberger; K Lechner; D Maurer; P Bettelheim
Journal:  Blood       Date:  1989-05-15       Impact factor: 22.113

4.  Effect of recombinant human erythropoietin on human IgE production in vitro.

Authors:  H Kimata; A Yoshida; C Ishioka; H Mikawa
Journal:  Clin Exp Immunol       Date:  1991-03       Impact factor: 4.330

5.  Erythropoietin receptor of a human leukemic cell line with erythroid characteristics.

Authors:  K Hitomi; K Fujita; R Sasaki; H Chiba; Y Okuno; S Ichiba; T Takahashi; H Imura
Journal:  Biochem Biophys Res Commun       Date:  1988-08-15       Impact factor: 3.575

6.  IgE-enhancing activity directly and selectively affects activated B cells: evidence for a human IgE differentiation factor.

Authors:  E H Sherr; L D Stein; H M Dosch; A Saxon
Journal:  J Immunol       Date:  1987-06-01       Impact factor: 5.422

7.  Phenotype of the accessory cell necessary for mitogen-stimulated T and B cell responses in human peripheral blood: delineation by its sensitivity to the lysosomotropic agent, L-leucine methyl ester.

Authors:  D L Thiele; M Kurosaka; P E Lipsky
Journal:  J Immunol       Date:  1983-11       Impact factor: 5.422

8.  Production of monoclonal antibodies against human erythropoietin and their use in the purification of human urinary erythropoietin.

Authors:  H Miyazaki; H Kozutsumi; T Kato; S Hoshi; S Tamura; M Kubota; T Suzuki
Journal:  J Immunol Methods       Date:  1988-10-26       Impact factor: 2.303

9.  Human recombinant IL-4 induces activated B lymphocytes to produce IgG and IgM.

Authors:  T Defrance; B Vanbervliet; J Pène; J Banchereau
Journal:  J Immunol       Date:  1988-09-15       Impact factor: 5.422

10.  IgE production by normal human lymphocytes is induced by interleukin 4 and suppressed by interferons gamma and alpha and prostaglandin E2.

Authors:  J Pène; F Rousset; F Brière; I Chrétien; J Y Bonnefoy; H Spits; T Yokota; N Arai; K Arai; J Banchereau
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

View more
  6 in total

1.  Nedocromil sodium acts directly on human B cells to inhibit immunoglobulin production without affecting cell growth.

Authors:  H Kimata; M Fujimoto; H Mikawa
Journal:  Immunology       Date:  1994-01       Impact factor: 7.397

2.  Recombinant human erythropoietin induces proliferation and Ca(2+)-influx in specific leukocyte subpopulations of rainbow trout (Oncorhynchus mykiss) blood and head kidney cells.

Authors:  S Körbel; T Bittorf; E Siegl; B Köllner
Journal:  J Comp Physiol B       Date:  2003-11-18       Impact factor: 2.200

3.  Long-term therapy with recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma.

Authors:  F Silvestris; A Romito; P Fanelli; A Vacca; F Dammacco
Journal:  Ann Hematol       Date:  1995-06       Impact factor: 3.673

4.  Characteristics of functional enrichment and gene expression level of human putative transcriptional target genes.

Authors:  Naoki Osato
Journal:  BMC Genomics       Date:  2018-01-19       Impact factor: 3.969

Review 5.  Iron in the Tumor Microenvironment-Connecting the Dots.

Authors:  Christa Pfeifhofer-Obermair; Piotr Tymoszuk; Verena Petzer; Günter Weiss; Manfred Nairz
Journal:  Front Oncol       Date:  2018-11-26       Impact factor: 6.244

6.  EpoR-tdTomato-Cre mice enable identification of EpoR expression in subsets of tissue macrophages and hematopoietic cells.

Authors:  Huan Zhang; Shihui Wang; Donghao Liu; Chengjie Gao; Yongshuai Han; Xinhua Guo; Xiaoli Qu; Wei Li; Shijie Zhang; Jingyu Geng; Linlin Zhang; Avital Mendelson; Karina Yazdanbakhsh; Lixiang Chen; Xiuli An
Journal:  Blood       Date:  2021-11-18       Impact factor: 22.113

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.